
|Videos|July 15, 2021
Treatment-Resistant Depression: Financial Support for Esketamine Therapy
Advertisement
Episodes in this series

Recommendations that can help clinicians navigate through the reimbursement process and best support patients who receive intranasal esketamine for treatment-resistant depression.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
2
The Postmodern Worldview and Contemporary Psychiatry
3
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
4
DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD
5





